Pier Capital LLC Purchases 26,479 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pier Capital LLC raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 43.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,497 shares of the medical equipment provider's stock after buying an additional 26,479 shares during the period. Pier Capital LLC owned 0.13% of Lantheus worth $7,827,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Quest Partners LLC grew its holdings in shares of Lantheus by 27,685.7% in the third quarter. Quest Partners LLC now owns 1,945 shares of the medical equipment provider's stock valued at $213,000 after acquiring an additional 1,938 shares in the last quarter. Pathstone Holdings LLC boosted its position in Lantheus by 18.9% in the third quarter. Pathstone Holdings LLC now owns 27,022 shares of the medical equipment provider's stock worth $2,966,000 after purchasing an additional 4,294 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Lantheus by 16.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,021 shares of the medical equipment provider's stock valued at $990,000 after purchasing an additional 1,286 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in shares of Lantheus during the 3rd quarter valued at $435,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the 3rd quarter worth $25,955,000. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last quarter. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

LNTH has been the subject of several research reports. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Truist Financial increased their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Trading Down 0.9 %

Shares of LNTH stock traded down $0.88 during trading on Friday, reaching $96.16. 617,660 shares of the company's stock traded hands, compared to its average volume of 942,021. The firm's 50-day moving average is $93.21 and its 200 day moving average is $96.42. The company has a market capitalization of $6.59 billion, a P/E ratio of 16.00 and a beta of 0.38. Lantheus Holdings, Inc. has a 1 year low of $58.16 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.